{
  "id": "enwiki-001364116887",
  "slug": "repotrectinib",
  "title": "Repotrectinib",
  "qid": "",
  "lead": "Repotrectinib, sold under the brand name Augtyro, is an anti-cancer medication used for the treatment of non-small cell lung cancer. It is taken by mouth. Repotrectinib is an inhibitor of proto-oncogene tyrosine-protein kinase ROS1 (ROS1) and of the tropomyosin receptor tyrosine kinases (TRKs) TRKA, TRKB, and TRKC. The most common adverse reactions include dizziness, dysgeusia, peripheral neuropathy, constipation, dyspnea, ataxia, fatigue, cognitive disorders, and muscular weakness. Repotrectinib was approved for medical use in the United States in November 2023, and in the European Union in January 2025.",
  "body": "Repotrectinib, sold under the brand name Augtyro, is an anti-cancer medication used for the treatment of non-small cell lung cancer. It is taken by mouth. Repotrectinib is an inhibitor of proto-oncogene tyrosine-protein kinase ROS1 (ROS1) and of the tropomyosin receptor tyrosine kinases (TRKs) TRKA, TRKB, and TRKC. The most common adverse reactions include dizziness, dysgeusia, peripheral neuropathy, constipation, dyspnea, ataxia, fatigue, cognitive disorders, and muscular weakness. Repotrectinib was approved for medical use in the United States in November 2023, and in the European Union in January 2025. Efficacy was evaluated in TRIDENT-1 (NCT03093116), a multicenter, single-arm, open-label, multi-cohort trial in 88 adult participants with locally advanced or metastatic neurotrophic tyrosine receptor kinase gene fusion-positive solid tumors who had either received a prior TRK tyrosine kinase inhibitor (TKI) (n=48) or were TKI-naïve (n=40). All participants were assessed for central nervous (CNS) lesions at baseline, and patients with symptomatic brain metastases were excluded. Tumor assessments were performed every eight weeks.",
  "categories": [
    "22900743",
    "23118434",
    "23603337",
    "24409354",
    "26483822",
    "27020709",
    "27362598",
    "32308905",
    "35379581",
    "50769796",
    "51734786",
    "60367775",
    "65000658",
    "68328988",
    "89598166",
    "90828262"
  ],
  "license": "CC BY-SA 4.0",
  "source_uri": "https://en.wikipedia.org/w/index.php?oldid=1364116887",
  "content_hash": "",
  "created_at": null,
  "updated_at": 1784038735.0,
  "claims": [],
  "contradictions": [],
  "confidence": 0.6,
  "csl": {
    "id": "enwiki-001364116887",
    "type": "webpage",
    "title": "Repotrectinib",
    "author": [
      {
        "family": "Anticloud FZ LLE",
        "literal": "Anticloud FZ LLE"
      }
    ],
    "container-title": "encyclopegia.org",
    "publisher": "Anticloud FZ LLE",
    "publisher-place": "Dubai, United Arab Emirates",
    "URL": "https://encyclopegia.org/a/repotrectinib",
    "issued": {
      "date-parts": [
        [
          2026,
          11,
          18
        ]
      ]
    },
    "accessed": {
      "date-parts": [
        [
          2026,
          11,
          18
        ]
      ]
    },
    "license": "CC BY-SA 4.0",
    "DOI": "eo1:enwiki-001364116887",
    "isBasedOn": "https://en.wikipedia.org/w/index.php?oldid=1364116887",
    "note": "Immutable snapshot enwiki-001364116887"
  }
}